Wedbush Issues Positive Forecast for CG Oncology (NASDAQ:CGON) Stock Price

CG Oncology (NASDAQ:CGON – Get Free Report) had its target price upped by analysts at Wedbush from $84.00 to $91.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush‘s price target indicates a potential upside of 7.34% from the stock’s previous close.

A number of other research firms have also recently issued reports on CGON. HC Wainwright raised their target price on shares of CG Oncology from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday. Royal Bank Of Canada downgraded shares of CG Oncology from an “outperform” rating to a “sector perform” rating and lifted their target price for the stock from $80.00 to $97.00 in a report on Tuesday. Piper Sandler upped their price target on shares of CG Oncology from $82.00 to $85.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Guggenheim lowered their price target on shares of CG Oncology from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Monday, November 9th. Finally, Wall Street Zen upgraded shares of CG Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 7th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $92.56.

Read Our Latest Stock Analysis on CG Oncology

CG Oncology Price Performance

Shares of CG Oncology stock opened at $84.78 on Tuesday. The business has a fifty day simple moving average of $68.24 and a two-hundred day simple moving average of $66.70. CG Oncology has a 1 year low of $37.01 and a 1 year high of $93.95. The company has a market capitalization of $7.57 billion, a price-to-earnings ratio of -30.72 and a beta of 0.35.

CG Oncology (NASDAQ:CGON – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.19. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $0.55 million. As a group, equities analysts anticipate that CG Oncology will post -3.00 earnings per share for the current fiscal year.

Insider Transactions at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $62.06, for a total value of $62,060.00. Following the transaction, the director directly owned 1,000 shares of the company’s stock, valued at $62,060. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 4.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On CG Oncology

Hedge funds and other institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its position in shares of CG Oncology by 4.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,728 shares of the company’s stock valued at $255,000 after acquiring an additional 175 shares during the period. Covestor Ltd increased its position in CG Oncology by 72.6% during the third quarter. Covestor Ltd now owns 770 shares of the company’s stock worth $55,000 after acquiring an additional 324 shares during the period. GAMMA Investing LLC increased its position in CG Oncology by 47.9% during the third quarter. GAMMA Investing LLC now owns 1,081 shares of the company’s stock worth $77,000 after acquiring an additional 350 shares during the period. Fiduciary Financial Advisors bought a new position in CG Oncology during the second quarter worth about $28,000. Finally, Manchester Capital Management LLC raised its stake in CG Oncology by 2,895.5% in the 3rd quarter. Manchester Capital Management LLC now owns 659 shares of the company’s stock worth $47,000 after purchasing an additional 637 shares in the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

Latest CG Oncology News

Here’s some of the latest news about CGON:

  • Positive Sentiment: In the PIVOT-006 trial, cretostimogene reduced the risk of bladder-cancer recurrence by 68% versus surveillance, meeting the primary endpoint with a hazard ratio of 0.32 (p<0.0001). The study enrolled 367 patients with intermediate-risk and high-grade Ta disease, a population of about 50,000 for which the company says there are no FDA-approved adjuvant treatments. Reuters article
  • Positive Sentiment: CG Oncology expects to use PIVOT-006 data in a second biologics license application (BLA), targeted for Q2 2027. The company also plans to broaden its initial BLA for BCG-unresponsive disease to include high-grade papillary-only patients, with submission completion expected by March 2027.
  • Neutral Sentiment: The results are topline and based on preliminary analysis. Regulatory approval is not assured; the FDA could request more data or studies, or approve a narrower label. The full trial results are scheduled for presentation at the Society of Urologic Oncology meeting on December 2.

CG Oncology Company Profile

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-GuĂ©rin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

Further Reading

Analyst Recommendations for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.